MedTrace Logo

Effect of CSII and CGM on Progression of Late Diabetic Complications

NCT01454700 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-01-14

No results posted yet for this study

Summary

The purpose of the study is to investigate whether the combination of insulin pump therapy and continued glucose monitoring (CGM) is superior to multiple daily insulin injections to prevent progression of albuminuria in patients with type 1 diabetes

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DEVICE

Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)

Randomization to 12 months with CSII plus CGM

OTHER

Multiple daily insulin injections (MDI)

Randomization12 months therapy with MDI

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Steen Andersen

    lead OTHER

Principal Investigators

  • Steen Andersen, MD, DMSc · Steno Diabetes Center Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01454700 on ClinicalTrials.gov